<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001425'>Heterogeneity</z:hpo> in the mechanisms of coagulation may contribute to an increased thrombotic risk for patients with <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The coincidence of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) have been described in several important epidemiological studies </plain></SENT>
<SENT sid="2" pm="."><plain>The pathological significance of aPL in patients with <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> is, however, still unclear </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we investigated the clinical manifestations of four patients with elevated IgM-aPL titres lying outside the region signifying 95% of <z:mpath ids='MPATH_458'>normal</z:mpath> cases and with a history of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The patients had elevated IgG- and IgM-anticardiolipin antibodies (aCL) and also tested positive for <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Other aPL were measured, and we found high positive results for <z:hpo ids='HP_0000001'>all</z:hpo> tested antibodies in three patients </plain></SENT>
<SENT sid="6" pm="."><plain>The production of aPL, however, occurred in the absence of thrombotic complications </plain></SENT>
<SENT sid="7" pm="."><plain>No thromboembolic manifestations occurred during the follow-up period either </plain></SENT>
<SENT sid="8" pm="."><plain>It could also be demonstrated that the degree to which the aCL titre was elevated resembles the elevation of the non-classical <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, but not that of beta2-GP-1 or anti-annexin antibodies </plain></SENT>
<SENT sid="9" pm="."><plain>Therefore, it can be postulated that these extremely high levels of IgM-aCL antibodies do not enhance the risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> and may be completely different from aCL antibodies in an <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> patient population without <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>In particular, haematological and lymphoproliferative <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> may indeed be associated with the generation of aPL, but do not necessarily enhance the thrombophilic risk in these patients </plain></SENT>
</text></document>